Bayer's Analyst Divide Widens: Jefferies Holds the Line While Rivals Chase 60 Euros

Analysts diverge sharply on Bayer after Q2 results: Jefferies sees no catalyst, while Goldman cites breakup potential. Legal delay adds uncertainty.

The gap between Wall Street's most cautious and most optimistic views on Bayer has rarely been wider. While UBS, DZ Bank and Goldman Sachs have all rushed to lift their price targets following the German conglomerate's second-quarter results, Jefferies is conspicuously staying put — a divergence that leaves investors weighing two very different narratives about the stock's future.

A Split Screen on Valuation

Jefferies analyst Michael Leuchten reaffirmed his "Hold" rating on Monday with a price target of 46 euros, making only minor tweaks to revenue and earnings forecasts. His reasoning is straightforward: he sees no near-term catalyst that would justify a more favourable valuation. Crucially, Leuchten does not expect a breakup of Bayer's agriculture and pharmaceutical divisions anytime soon — a scenario that other analysts have flagged as a potential trigger for a re-rating.

That puts Jefferies at odds with Goldman Sachs, which explicitly cited the removal of a conglomerate discount as a long-term share price driver when it raised its target to 63.50 euros. The spectrum of analyst opinion is now remarkably broad: Goldman Sachs, UBS and DZ Bank sit at the optimistic end with targets between 60 and 63.50 euros, while Jefferies anchors the cautious camp at 46 euros — barely above the current trading level. JPMorgan occupies the middle ground with a confirmed 50-euro target, and even suggests consensus expectations for full-year core earnings could be revised upward.

The Numbers Behind the Disagreement

The divergence in analyst sentiment is rooted in a mixed quarterly performance. Bayer's Crop Science division impressed with a 30.2 percent rise in adjusted earnings in the second quarter, but the pharmaceuticals unit earned 3.6 percent less over the same period. Overall core earnings per share fell 16.7 percent year-on-year — a figure that lends some credibility to the cautious camp, even though management maintained its full-year guidance.

The company also beat profit and operational expectations and accelerated its debt reduction, which helped fuel the more optimistic analyst responses. On the technical side, a breakout above the 54-euro mark is widely seen as the prerequisite for a move toward the 60-euro level that several analysts now cite as their target.

Legal Calendar Looms

The unresolved glyphosate litigation continues to hang over the stock. A hearing for final approval of the multibillion-dollar settlement — originally scheduled for August 19 — has been pushed back to September 14. While the basic agreement worth 7.25 billion US dollars has already received preliminary approval, the delay keeps a degree of uncertainty alive.

Bayer has spent more than 11 billion US dollars on settlements and judgments related to Roundup claims since acquiring Monsanto in 2018. A provision in the US Farm Bill for 2026 that would have offered Bayer broad protection from certain types of lawsuits was removed via amendment in April before the revised version passed. A legally anchored shield therefore does not currently exist, though a US government order supporting glyphosate production signals the political environment is at least not deteriorating further.

Where the Stock Stands

Bayer shares are currently trading at 48.87 euros, slightly below Tuesday's closing price of 49.12 euros. That leaves the stock roughly 9.26 percent below its 52-week high of 53.86 euros, reached in early July. The shares remain comfortably above their 50-day moving average, pointing to intact short-term upward momentum, and have gained around a third since the start of the year.

The current price zone neither confirms the enthusiasm of the more optimistic analysts nor validates Jefferies' caution — an unsurprising state of affairs given the wide spread between price targets. For investors, the takeaway is that Bayer's valuation now hinges heavily on how much weight one places on structural change — a potential breakup or the full resolution of legal disputes — versus the near-term operational metrics that Jefferies prioritises.